RAD101's Phase 2b concordance data sets up a Phase 3 bet on whether a radiopharmaceutical imaging agent can redefine brain metastasis diagnosis — but survival to that readout is the immediate question

Bull

A confirmed ≥85–90% concordance rate at the primary endpoint readout would validate RAD101 as a clinically differentiated PET imaging agent for recurrent brain metastases, providing the data package needed to open a constructive FDA dialogue and formally initiate the Phase 3 registrational trial; this outcome would also de-risk the Siemens Healthineers supply agreement as strategically well-timed, potentially attracting partnership interest and supporting a re-rating of the stock around a credible registration pathway.

Bear

The primary risk is that the full-cohort concordance rate falls below the pre-specified threshold, whether due to patient selection variability, lesion heterogeneity in later-enrolled patients, or MRI comparator inconsistencies across sites — any of these could undermine the regulatory case for Phase 3; a secondary risk is that even with positive data, the company's cash runway (approximately $19M with a ~$15M quarterly burn) may not support Phase 3 initiation without a dilutive raise, effectively neutralizing a positive readout.